AustriaAustria

f-star inks EUR1.26bn antibody development deal with Boehringer Ingelheim

25.11.2010

Vienna – Boehringer Ingelheim has secured access to another promising antibody technology through a licence and development deal with Austrian f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H worth up to EUR1.26bn. Under the terms of this largest deal ever achieved by an Austrian biotech company, f-star will develop antibodies based on its proprietary Modular Antibody Technology (MAT) against 7 targets selected by the German drugmaker. Albeit the amount of the upfront payment was not disclosed it was announced that Boehringer is to pay up to EUR180m for every successful programme including research-based funding, licence fees, development, regulatory and commercial milestones plus royalties on product sales. The collaboration will focus on two proprietary antibody format of f-star – FCABs and MAB2. FCABs are antibody fragments with full functionality but only one third of the size of full-lengh monoclonal antibodies, MAB2 are full length bi-specific IgG antibodies with 2 additional functionalities engineered into the constant CDR regions. The market for therapeutic mABs reached global revenues of $36.4bn last year and is estimated to expand to $62,7bn until 2015, according to Datamonitor analyses. Besides the Boehringer contract F-star has been running 10 antibody programmes in-house since it was spun-off from Vienna-based BOKU.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/f-star-inks-eur126bn-antibody-development-deal-with-boehringer-ingelheim.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • MERCK KGAA72.63 EUR4.35%
  • MAGFORCE7.30 EUR4.29%

FLOP

  • CYTOS0.21 CHF-8.70%
  • WILEX2.22 EUR-5.93%
  • CO.DON3.08 EUR-5.81%

TOP

  • PAION3.25 EUR31.0%
  • CO.DON3.08 EUR23.2%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • CYTOS0.21 CHF-19.2%
  • ADDEX3.25 CHF-18.8%
  • MEDIGENE3.86 EUR-17.0%

TOP

  • SANTHERA89.30 CHF2088.7%
  • CO.DON3.08 EUR234.8%
  • PAION3.25 EUR221.8%

FLOP

  • CYTOS0.21 CHF-94.8%
  • BIOFRONTERA2.24 EUR-38.6%
  • 4SC1.14 EUR-38.4%

No liability assumed, Date: 22.09.2014


Current issue

All issues

Product of the week

Products